SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma gains on inking pact with Lundbeck to market, distribute Vortioxetine in India

30 Mar 2022 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 920.05, up by 0.55 points or 0.06% from its previous closing of Rs. 919.50 on the BSE.

The scrip opened at Rs. 920.00 and has touched a high and low of Rs. 921.95 and Rs. 908.30 respectively. So far 66897 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 930.90 on 21-Mar-2022 and a 52 week low of Rs. 587.50 on 30-Mar-2021.

Last one week high and low of the scrip stood at Rs. 921.95 and Rs. 885.55 respectively. The current market cap of the company is Rs. 220606.85 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 33.99% and 11.53% respectively.

Sun Pharmaceutical Industries has entered into an exclusive patent licensing agreement with H. Lundbeck A/S (Lundbeck) to market and distribute its own version of Vortioxetine in India under the brand name, ‘Vortidif’. The territory of the licensing agreement will only cover India.

Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries, including the US, EU, Canada and Australia.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.


Sun Pharma Inds. Share Price

1670.40 -4.80 (-0.29%)
20-Apr-2026 12:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.40
Dr. Reddys Lab 1236.50
Cipla 1234.00
Zydus Lifesciences 942.40
Lupin 2332.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×